Journal Club #2:
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
Article: Psychother Psychosom. 2019;88(5):263-273.
This 25 minutes journal club video discussion will answer the following 10 clinically relevant questions:
- Are omega-3 fatty acids effective as augmentation or as monotherapy for MDD management?
- What dose of omega-3 fatty acid is considered therapeutic for the treatment of MDD?
- What ratio of EPA/DHA is crucial for omega-3 fatty acids’s therapeutic benefit?
- Is pure EHA more efficacious than the combination of EHA/DHA for MDD?
- What is the recommended minimum duration of treatment with omega-3 fatty acid for the treatment of MDD?
- Is omega-3 fatty acid efficacious for recurrent depression?
- What are the common adverse events at the therapeutic dose of omega-3 fatty acid?
- What additional lab work is required when using the higher dosages of omega-3 fatty acid?
- How to ensure the omega-3 fatty acid’s product quality before buying?
- Do omega-3 fatty acid’s response in MDD have a relation with inflammatory biomarkers?